# Biotia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biotia

- Industry: Healthcare IT
- Headquarters: Long Island City, US
- Website: www.biotia.io
- Total disclosed funding: $11M
- Latest round: Series A (Aug 23, 2022)
- Investors on record: 15

## About

Biotia, Inc. is a biotechnology firm focused on advanced infectious disease diagnostics utilizing genomics and artificial intelligence to enhance diagnostic accuracy and efficiency.Biotia, Inc. was founded in 2016 and is headquartered in Brooklyn, US. The company specializes in genomics-based diagnostics, evolving its strategy to provide innovative solutions for infectious diseases. The co-founders include Christopher Mason, Niamh Ohara, and Rachid O, with Niamh Ohara serving as the CEO. In October 2026, Biotia, Inc. raised USD 9 million in venture funding from Convergent Ventures, I-Lab Angels, EGB Capital, Red Bear Angels, Red Bear Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, and Leawood Venture Capital. Biotia specializes in advanced infectious disease diagnostics powered by genomics and artificial intelligence (AI). The company's primary offerings include BIOTIA-DX and BIOTIA-ID, clinically validated metagenomics tools designed to enhance traditional diagnostic methods. BIOTIA-DX enables precise organism identification with heightened sensitivity, while BIOTIA-ID is a comprehensive assay with regulatory approvals aimed at immunocompromised individuals and those facing complicated infections. Additionally, the BIOTIA-ID Urine assay provides a novel solution to improve detection rates of various pathogens. Biotia's products are utilized across markets including North America, South America, Europe, and parts of Africa, serving local laboratories, healthcare providers, and research institutions dedicated to infectious disease diagnostics.Biotia generates revenue through direct sales, partnerships, and collaborative agreements with esteemed healthcare institutions, such as the Mayo Clinic and the Rockefeller Foundation. Its key products, BIOTIA-DX and BIOTIA-ID, are sold as laboratory-developed tests (LDTs) to healthcare facilities that incorporate them into their workflows. The company operates on a B2B revenue model, with transactions facilitated through agreements that may involve subscription services or one-time payments for specific assays, enhancing its revenue streams in the infectious disease sector. The company will use the October 2026 funding to support development of new women’s health diagnostics, expand into orthopedics, grow its New York City lab, expand its test menu, pursue reimbursement, and increase clinician access to its diagnostic tools.

## Funding rounds

- Series A, Aug 23, 2022, $8M — OCA Ventures, Phoenix Venture Partners, Hyperplane Venture Capital, Leawood Venture Capital, DigitalDx Ventures, Falcon III Ventures, Tau Ventures, SeedtoB Capital, SK Square CO., LTD., Continuum Health Ventures, SpringTide Capital Management
- Seed, Dec 10, 2019, $2.4M — Cloquet Capital Partners, Hyperplane Venture Capital, Falcon III Ventures
- Seed, May 29, 2019, $0.3M — SpringTide Capital Management
- Seed, Mar 15, 2019 — Everywhere Ventures, Tau Ventures
- Seed, Dec 20, 2018 — Amplifyher Ventures
- Seed, Apr 1, 2018 — Third Act Ventures

## Investors

- Third Act Ventures (https://capitalatlas.ai/funds/third-act-ventures) — Seed
- Amplifyher Ventures (https://capitalatlas.ai/funds/amplifyher-ventures) — Seed
- Everywhere Ventures (https://capitalatlas.ai/funds/everywhere-ventures) — Seed
- Tau Ventures — Seed, Series A
- SpringTide Capital Management (https://capitalatlas.ai/funds/springtide-capital-management) — Seed, Series A
- Cloquet Capital Partners (https://capitalatlas.ai/funds/cloquet-capital-partners) — Seed
- Hyperplane Venture Capital (https://capitalatlas.ai/funds/hyperplane-venture-capital) — Seed, Series A
- Falcon III Ventures — Seed, Series A
- OCA Ventures (https://capitalatlas.ai/funds/oca-ventures) — Series A
- Phoenix Venture Partners — Series A
- Leawood Venture Capital (https://capitalatlas.ai/funds/leawood-venture-capital) — Series A
- DigitalDx Ventures (https://capitalatlas.ai/funds/digitaldx-ventures) — Series A
- SeedtoB Capital (https://capitalatlas.ai/funds/seedtob-capital) — Series A
- SK Square CO., LTD. — Series A
- Continuum Health Ventures (https://capitalatlas.ai/funds/continuum-health-ventures) — Series A